UNDERSTANDING AUTOREACTIVE T CELL PATHOGENICITY
了解自身反应性 T 细胞致病性
基本信息
- 批准号:8835343
- 负责人:
- 金额:$ 38.13万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2015
- 资助国家:美国
- 起止时间:2015-05-05 至 2020-04-30
- 项目状态:已结题
- 来源:
- 关键词:AutoantigensAutoimmune DiseasesAutoimmunityBehaviorCD28 geneCD4 Positive T LymphocytesCell physiologyCellsEventExperimental Autoimmune EncephalomyelitisGene TargetingGenesGenetic TranscriptionGoalsGranulocyte-Macrophage Colony-Stimulating FactorGreen Fluorescent ProteinsHelper-Inducer T-LymphocyteImmuneImmune responseImmunizationImmunosuppressive AgentsIn VitroInterferonsInterleukin-1Interleukin-10Interleukin-17LaboratoriesMediatingModelingMolecularMultiple SclerosisMusNeuraxisPathogenicityPlayPopulationProcessProductionProteinsReceptor SignalingRegulationRegulator GenesReporterReportingResistanceRoleSignal TransductionSupplementationSystemT-LymphocyteTestingTranscription CoactivatorTranscription Repressor/CorepressorTranscriptional RegulationWorkautoreactive T cellbasecell typecytokineinsightmouse modelneuroinflammationnew therapeutic targetpreventpublic health relevanceresearch studyresponsetranscription factor
项目摘要
DESCRIPTION (provided by applicant): CD4 T helper (TH) cells drive autoimmunity through their production of proinflammatory cytokines. The molecular determinants controlling the cytokine production and pathogenicity of autoreactive T cells remain unclear. In experimental autoimmune encephalomyelitis (EAE), a mouse model of multiple sclerosis (MS), TH1, TH17 infiltrate the central nervous system (CNS). Remarkably, IFN-� and IL-17, the hallmark cytokines produced by TH1 and TH17 lineages, are not required for encephalitogenicity. Instead, the TH cell- cell-derived cytokine granulocyte-macrophage colony stimulating factor (GM-CSF, encoded by Csf2) plays a nonredundant role in mediating neuroinflammation. Immunosuppressive cytokines produced by autoreactive T cells, including IL-10, also influence T cell encephalitogenicity. We have discovered that mice deficient for the transcription factor Bhlhe40 are resistant to the induction of EAE. Bhlhe40-/- TH cells produce normal amounts of their hallmark cytokines, but produce decreased amounts of GM-CSF and increased amounts of IL-10. We will test the central hypothesis that Bhlhe40 is a required determinant for the pathogenicity of autoreactive T cells. In Aim 1, we will determine the mechanistic basis for Bhlhe40 function in neuroinflammation, testing the hypothesis that the nonencephalitogenicity of Bhlhe40-/- T cells is due to their cell-intrinsic IL-10 production. We will also test the hypothesi that Bhlhe40 acts as a direct transcriptional regulator of genes controlling autoreactive TH cell pathogenicity and determine the structural features of the Bhlhe40 protein required for this transcriptional regulation. In Aim 2, we will use Bhlhe40-green fluorescent protein (GFP) reporter mice to identify the signals that induce Bhlhe40 expression in T cells and test the hypothesis that Bhlhe40 expression determines the pathogenicity of autoreactive T cells. These studies will contribute to our understanding of how T cells acquire autoaggressive effector functions and could identify Bhlhe40 as a novel therapeutic target for the treatment of autoimmune disease.
描述(由申请人提供):CD4T辅助(TH)细胞通过产生促炎细胞因子来驱动自身免疫。控制细胞因子产生和自身反应性T细胞致病性的分子决定因素仍不清楚。在实验性自身免疫性脑脊髓炎(EAE)中,多发性硬化症(MS)的小鼠模型中,TH1、TH17侵袭中枢神经系统(CNS)。值得注意的是,由Th1和Th17谱系产生的标志性细胞因子干扰素-�和IL-17不是脑炎发生所必需的。相反,TH细胞衍生的细胞因子粒细胞-巨噬细胞集落刺激因子(GM-CSF,由CSF2编码)在介导神经炎症方面发挥着非多余的作用。自身反应性T细胞产生的免疫抑制细胞因子,包括IL-10,也影响T细胞的脑原性。我们发现,缺乏转录因子Bhlhe40的小鼠对EAE的诱导具有抵抗力。Bhlhe40-/-TH细胞产生正常数量的标志性细胞因子,但产生数量减少的GM-CSF和增加数量的IL-10。我们将检验核心假设,即Bhlhe40是自身反应性T细胞致病所必需的决定因素。在目标1中,我们将确定Bhlhe40在神经炎症中作用的机制基础,验证Bhlhe40-/-T细胞的非脑原性是由于其细胞内源性IL-10产生的假设。我们还将测试Bhlhe40作为控制自身反应性TH细胞致病性的基因的直接转录调节因子的假设,并确定这种转录调节所需的Bhlhe40蛋白的结构特征。在目标2中,我们将使用Bhlhe40-绿色荧光蛋白(GFP)报告小鼠来鉴定诱导Bhlhe40在T细胞中表达的信号,并验证Bhlhe40表达决定自身反应性T细胞致病性的假设。这些研究将有助于我们理解T细胞是如何获得自身侵袭性效应功能的,并可能确定Bhlhe40是治疗自身免疫性疾病的新治疗靶点。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Brian Todd Edelson其他文献
Brian Todd Edelson的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Brian Todd Edelson', 18)}}的其他基金
Selective induction of alloantigen-specific humoral tolerance by MHC-Fc fusion proteins
MHC-Fc 融合蛋白选择性诱导同种异体抗原特异性体液耐受
- 批准号:
10432434 - 财政年份:2022
- 资助金额:
$ 38.13万 - 项目类别:
Role of Intestinal Parasites on Regulating Immune Responses to Gut Antigens
肠道寄生虫在调节肠道抗原免疫反应中的作用
- 批准号:
10445670 - 财政年份:2022
- 资助金额:
$ 38.13万 - 项目类别:
Role of Intestinal Parasites on Regulating Immune Responses to Gut Antigens
肠道寄生虫在调节肠道抗原免疫反应中的作用
- 批准号:
10651714 - 财政年份:2022
- 资助金额:
$ 38.13万 - 项目类别:
Selective induction of alloantigen-specific humoral tolerance by MHC-Fc fusion proteins
MHC-Fc 融合蛋白选择性诱导同种异体抗原特异性体液耐受
- 批准号:
10612453 - 财政年份:2022
- 资助金额:
$ 38.13万 - 项目类别:
Immunologic Characterization of CSF microglia in multiple sclerosis
多发性硬化症脑脊液小胶质细胞的免疫学特征
- 批准号:
10196298 - 财政年份:2021
- 资助金额:
$ 38.13万 - 项目类别:
Immunologic Characterization of CSF microglia in multiple sclerosis
多发性硬化症脑脊液小胶质细胞的免疫学特征
- 批准号:
10374170 - 财政年份:2021
- 资助金额:
$ 38.13万 - 项目类别:
Regulation of Immune Responses to Mycobacterium tuberculosis Infection
结核分枝杆菌感染免疫反应的调节
- 批准号:
10465067 - 财政年份:2018
- 资助金额:
$ 38.13万 - 项目类别:
Regulation of Immune Responses to Mycobacterium tuberculosis Infection
结核分枝杆菌感染免疫反应的调节
- 批准号:
10231224 - 财政年份:2018
- 资助金额:
$ 38.13万 - 项目类别:
Regulation of Immune Responses to Mycobacterium tuberculosis Infection
结核分枝杆菌感染免疫反应的调节
- 批准号:
9789818 - 财政年份:2018
- 资助金额:
$ 38.13万 - 项目类别:
UNDERSTANDING AUTOREACTIVE T CELL PATHOGENICITY
了解自身反应性 T 细胞致病性
- 批准号:
9247751 - 财政年份:2015
- 资助金额:
$ 38.13万 - 项目类别:
相似国自然基金
Autoimmune diseases therapies: variations on the microbiome in rheumatoid arthritis
- 批准号:31171277
- 批准年份:2011
- 资助金额:60.0 万元
- 项目类别:面上项目
相似海外基金
Autoantibodies and antibody-secreting cells in neurological autoimmune diseases: from biology to therapy
神经性自身免疫性疾病中的自身抗体和抗体分泌细胞:从生物学到治疗
- 批准号:
479128 - 财政年份:2023
- 资助金额:
$ 38.13万 - 项目类别:
Operating Grants
Effects of maternal immune activation on autoimmune diseases in offsprings
母体免疫激活对后代自身免疫性疾病的影响
- 批准号:
23H02155 - 财政年份:2023
- 资助金额:
$ 38.13万 - 项目类别:
Grant-in-Aid for Scientific Research (B)
IPP: AUTOIMMUNE DISEASES STATISTICAL AND CLINICAL COORDINATING CENTER (ADSCCC)
IPP:自身免疫性疾病统计和临床协调中心 (ADSCCC)
- 批准号:
10788032 - 财政年份:2023
- 资助金额:
$ 38.13万 - 项目类别:
Biomarkers of vascular endothelial dysfunction in systemic autoimmune diseases: analysis of circulating microRNAs
系统性自身免疫性疾病中血管内皮功能障碍的生物标志物:循环 microRNA 分析
- 批准号:
23K14742 - 财政年份:2023
- 资助金额:
$ 38.13万 - 项目类别:
Grant-in-Aid for Early-Career Scientists
Structural mechanisms of autoimmune diseases targeting cys-loop receptors
针对半胱氨酸环受体的自身免疫性疾病的结构机制
- 批准号:
10864719 - 财政年份:2023
- 资助金额:
$ 38.13万 - 项目类别:
Developing non-immunosuppressive immune-based therapeutics for targeted treatment of autoimmune diseases
开发非免疫抑制性免疫疗法来靶向治疗自身免疫性疾病
- 批准号:
10586562 - 财政年份:2023
- 资助金额:
$ 38.13万 - 项目类别:
NOVEL HUMORAL AND CELLULAR BIOMARKERS OF AUTOIMMUNE DISEASES CAUSED BY IMMUNOTHERAPY
免疫治疗引起的自身免疫性疾病的新型体液和细胞生物标志物
- 批准号:
10593224 - 财政年份:2023
- 资助金额:
$ 38.13万 - 项目类别:
Regulation of autoimmune diseases by PTPN22 phosphatase
PTPN22磷酸酶对自身免疫性疾病的调节
- 批准号:
23K06589 - 财政年份:2023
- 资助金额:
$ 38.13万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Decipher and target GABA metabolism and GABA receptor-mediated signaling in autoimmune diseases
破译并靶向自身免疫性疾病中的 GABA 代谢和 GABA 受体介导的信号传导
- 批准号:
10623380 - 财政年份:2023
- 资助金额:
$ 38.13万 - 项目类别:
Targeting the long isoform of the prolactin receptor to treat autoimmune diseases and B-cell malignancies
靶向催乳素受体的长亚型来治疗自身免疫性疾病和 B 细胞恶性肿瘤
- 批准号:
10735148 - 财政年份:2023
- 资助金额:
$ 38.13万 - 项目类别:














{{item.name}}会员




